← feed

Is NCT03430154 results overdue?

Yes — results are overdue. Primary completion was 2018-04-29; the FDAAA-801 reporting deadline (2019-04-29) passed 2656 days ago and no results are posted on ClinicalTrials.gov.

Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)

NCT IDNCT03430154 ↗
SponsorNovo Nordisk A/S (INDUSTRY)
Public issuerNOVO NORDISK A S — NVO (CIK 0000353278) best-effort name match, 95% conf — verify on EDGAR ↗
Phase
StatusCOMPLETED
Primary completion2018-04-29 (ACTUAL)
Reporting deadline2019-04-29 (completion + 365d)
Days overdue2656
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 d15bbe6fbc0c3716… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03430154. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →